Aptose Biosciences(US:APTO)2026-03-31 21:29Clinical Development of Tuspetinib - Aptose's lead program, Tuspetinib, is being developed for frontline combination therapy in newly diagnosed acute myeloid leukemia (AML) patients, addressing a significant unmet need in this aggressive cancer type [274]. - In a Phase 1/2 clinical trial, Tuspetinib demonstrated a complete response (CR) rate of 36% among all R/R AML patients, with a 50% CR rate in patients with mutated FLT3 [278]. - The TUS+VEN doublet combination therapy maintained a favorable safety profile with no new safety signals observed, achieving significant clinical responses in heavily pretreated R/R AML patients [279]. - The ongoing TUSCANY trial reported a 100% response rate (CR/CRh) at higher dose levels (80 mg and 120 mg) for newly diagnosed AML patients [287]. - The FDA granted orphan drug designation to Tuspetinib for AML treatment, providing seven additional years of marketing exclusivity and various development incentives [283]. - The MyeloMATCH trials, launched in May 2024, aim to expedite tailored drug combination treatments for newly diagnosed AML and myelodysplastic syndromes (MDS) patients [285]. - Aptose's collaboration with the National Cancer Institute (NCI) under a Cooperative Research and Development Agreement (CRADA) focuses on the clinical development of Tuspetinib in targeted therapy combinations [284]. - The TUS+VEN+AZA triplet therapy is expected to establish a new standard of care for newly diagnosed AML patients, particularly those with adverse genetic abnormalities [280]. - The company anticipates delivering important clinical data over the next 6 to 12 months as the Phase 1/2 trial progresses [277]. - TUS in combination with standard dosing of VEN+AZA achieved complete responses (CR/CRh) in 6 out of 6 (100%) patients at higher dose levels of 80 mg and 120 mg, exceeding the expected 66% response rate from VEN+AZA alone [293]. - Overall, TUS+VEN+AZA achieved CR/CRh responses in 9 out of 10 (90%) patients, with 7 out of 9 (78%) responding patients showing minimal residual disease (MRD) negativity [293]. - The safety review committee endorsed escalation to 160 mg TUS dosing, with no dose-limiting toxicities (DLTs) reported across cohorts of 40 mg, 80 mg, and 120 mg TUS [297]. - TUS+VEN+AZA triplet therapy is being developed as a mutation-agnostic frontline treatment for newly diagnosed AML patients ineligible for induction chemotherapy, showing efficacy across diverse mutational subtypes [295]. - At the 40 mg TUS dose level, three out of four patients achieved CRs and were MRD-negative, including patients with FLT3-ITD, FLT3-WT, and TP53/CK mutations [298]. - The TUS+VEN combination demonstrated a favorable safety profile with no treatment-related deaths, QTc prolongation, or prolonged myelosuppression reported [302]. - TUS can be safely administered with standard-of-care dosing of VEN/AZA, with pharmacokinetic analyses showing no significant interactions affecting plasma levels [302]. - The triplet therapy continues to achieve CRs and MRD-negativity with favorable safety in newly diagnosed AML patients, indicating a strong potential for commercial opportunity [295]. - TUS+VEN+AZA triplet may establish a more effective, mutation-agnostic standard of care for chemotherapy-ineligible AML patients, with 60% and 42% CR/CRh rates observed in FLT3 mutated and all-comer VEN-naïve AML patients [311]. - Tuspetinib monotherapy achieved a complete remission (CRc) rate of 42% and an overall response rate (ORR) of 50% in patients who were naive to Venetoclax (VEN) and those with FLT3 mutations [314]. - In the TUS+VEN doublet therapy, an overall CRc rate of 25% was observed among evaluable patients, with a 43% CRc rate in VEN-naive patients and a 21% CRc rate in prior-VEN patients [321]. - The APTIVATE Phase 1/2 trial has shown that TUS+VEN is well tolerated, with no unexpected safety signals, and has achieved an ORR of 48% among all evaluable patients [323]. - Tuspetinib has demonstrated broad clinical activity across various genetic subgroups, including TP53, RAS/MAPK, and FLT3 mutants, addressing a significant unmet medical need in relapsed/refractory AML [320]. - The combination of Tuspetinib with VEN and Azacitidine (TUS+VEN+HMA) is being developed to enhance response rates and improve overall survival in newly diagnosed AML patients [318]. - The median overall survival (OS) for relapsed/refractory AML patients receiving chemotherapy after failing prior therapy with HMA-VEN was only 7.2 months, highlighting the need for improved treatment options [314]. - Tuspetinib has shown a favorable safety profile with no dose-limiting toxicities (DLTs) up to 160 mg per day, allowing for its use in combination therapies [321]. - The ongoing clinical program has enrolled over 170 patients in the Phase 1/2 trial, demonstrating significant response rates in a heavily pre-treated population [316]. - The TUS+VEN combination has been particularly effective in patients with prior failure of VEN, achieving a 44% ORR in this subgroup [323]. - Preliminary pharmacokinetic data suggest no clinically meaningful interaction between Tuspetinib and VEN, facilitating their co-administration [320]. - Tuspetinib monotherapy demonstrated a 29% complete response (CR/CRh) rate in R/R AML patients with RAS gene mutations [327]. Financial Performance - The company reported a net loss of $25.5 million for the year ended December 31, 2025, compared to a loss of $25.4 million for 2024 [347]. - As of December 31, 2025, the company had an accumulated deficit of $566.4 million, up from $541.0 million in 2024 [347]. - Cash, cash equivalents, restricted cash, and restricted cash equivalents decreased to $4.1 million as of December 31, 2025, from $6.7 million in 2024 [347]. - The company has a working capital deficit of $2.9 million as of December 31, 2025, compared to a positive working capital of $5.1 million in 2024 [344]. - The company has fully utilized $8.5 million under the Hanmi Facility Agreement and $11.9 million under the Amended Facility Agreement [341]. - An additional uncommitted facility of up to $11.1 million was provided by Hanmi under the Second Amended Facility Agreement for continued clinical development of tuspetinib [341]. - The company received a deficiency letter from Nasdaq regarding the minimum bid price requirement, with a deadline to regain compliance by January 13, 2025 [333]. - The company plans to raise additional funds through debt or other financing activities to support operations [348]. - The company may face challenges in raising capital due to adverse market conditions and its product pipeline status [349]. - The company reported a net cash used in operating activities of $22.0 million for the year ended December 31, 2025, a decrease of $14.0 million compared to $36.0 million in 2024 [372]. - Cash flows from financing activities for the year ended December 31, 2025, amounted to $19.4 million, primarily from advances under the Hanmi Facility Agreements totaling $18.6 million [374]. - The company completed a public offering on January 30, 2024, raising aggregate gross proceeds of $9.7 million from the sale of 188,304 Common Shares at a price of $51.30 per share [359]. - The November 2024 Public Offering generated gross proceeds of $8.0 million from the sale of 1,333,333 Common Shares at $6.00 per share [353]. - The company issued 137,000 Common Shares under the 2025 ATM Facility at an average price of $7.31 per share, resulting in gross proceeds of $1.0 million [352]. - The company raised a total of $2.1 million of gross proceeds under the 2022 ATM Facility, with 2,717 Common Shares issued at an average price of $36.60 per share [369]. - The company issued 17,003 Common Shares to Keystone at an average price of $40.80 per share for cash proceeds of $0.7 million during the year ended December 31, 2024 [366]. - The company completed a Registered Direct Offering on June 3, 2024, raising approximately $4.4 million from the sale of 60,000 Common Shares at $34.50 per share [358]. - The company recognized $0.2 million of financing costs associated with professional fees related to the 2023 Committed Equity Facility [368]. - The company does not expect to generate positive cash flow from operations in the foreseeable future due to ongoing research and development costs [372]. - For the year ended December 31, 2025, the company reported a net loss of $25.5 million, slightly increasing from a net loss of $25.4 million in 2024 [380]. - Research and development (R&D) expenses decreased by $3.8 million to $11.3 million in 2025, compared to $15.1 million in 2024 [382]. - General and administrative expenses increased by $2.2 million to $13.4 million in 2025, up from $11.2 million in 2024 [388]. - The company has maximum obligations for clinical development and global regulatory milestones totaling $64.5 million for the first indication of tuspetinib, with additional obligations of $34.0 million and $29.0 million for subsequent indications [379]. - As of December 31, 2025, the company recorded $4.1 million in prepaid expenses and $3.2 million in accrued liabilities related to R&D activities [393]. - The company expects general and administrative expenses to increase slightly in the near term due to ongoing personnel costs and legal fees [384]. - Program costs for tuspetinib decreased by $1.7 million to $7.9 million in 2025, compared to $9.6 million in 2024 [387]. - Personnel-related expenses for R&D decreased by $1.8 million to $2.9 million in 2025, down from $4.7 million in 2024 [387]. - The company has not entered into any off-balance sheet arrangements as of December 31, 2025 [377]. - As of March 16, 2026, the company had 2,552,429 Common Shares issued and outstanding, with additional shares issuable upon the exercise of stock options and warrants [394].